Description
Hepatitis Virus Testing Market size was valued at USD 2.9 billion in 2021, growing at a CAGR of 4.8% from 2022 to 2028. Liver is an essential organ of the body in which performs critical functions that affect the metabolism in the body. Hepatitis refers to the inflammatory condition of the liver and caused by the viral infection or medications. Hepatitis is considered as the sexually transmitted disease. Hepatitis can be classified into hepatitis A, hepatitis, B, hepatitis C, based on the virus. These are confirmed through the laboratory tastings. Various tests are available in the market based on the type of hepatitis. Industry trends in the market are evolving, which will aid players in developing successful long-term strategies. Both established and emerging markets have implemented business growth techniques. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. Hepatitis Virus Testing Market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.
Key Developments:
In March 2017, U.S. Food and Drug Administration has approved Siemens Healthineer’s Versant HCV Genotype 2.0 line probe (LiPA) for HCV testing.